NCT04009057View on ClinicalTrials.gov

Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

CompletedOBSERVATIONAL
Enrollment

143

Participants

Timeline

Start Date

July 9, 2019

Primary Completion Date

March 21, 2022

Study Completion Date

March 21, 2022

Conditions
HIV-1-infection
Interventions
OTHER

B/F/TAF

B/F/TAF administered in accordance with the approved product monograph

Trial Locations (5)

52621

Sheba Medical Center, Tel Litwinsky

76100

Kaplan Medical Center, Rehovot

3109601

Rambam Medical Center, Haifa

6423906

Tel Aviv Souraski Medical Center, Tel Aviv

Unknown

Hadassah Medical Center, Jerusalem

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY